RNXT

RenovoRx Inc

1.04

Nov 13 • 3:59 PM ET -0.12 (-10.34%)

1.04

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Micro NASD

Peers: ONCY ELTX DRTS NBTX OBIO PMCB PPCB SLXN IMNN PCSA

| Held by: VTI VXF

Scroll to Statements

Index	-
Market Cap	50.18M
Enterprise Value	40.14M
Income	-13.02M
Sales	2.78M
Book/sh	0.19
Cash/sh	0.22
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	17
IPO	Aug 26, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	18.05
P/B	5.40
P/C	4.83
P/FCF	-
EV/EBITDA	-
EV/Sales	14.44
Quick Ratio	5.49
Current Ratio	5.65
Debt/Eq	0.04
LT Debt/Eq	0.02
Option/Short	No / Yes

EPS (ttm)	-0.31
EPS next Y	-0.10
EPS next Q	-0.06
EPS this Y	17.97%
EPS next Y	60.95%
EPS next 5Y	-
EPS past 3/5Y	33.86% 6.34%
Sales past 3/5Y	- -
EPS Y/Y TTM	12.75%
Sales Y/Y TTM	199.14%
EPS Q/Q	4.78%
Sales Q/Q	300.75%
Earnings	Nov 05 AMC
EPS/Sales Surpr.	-33.33% 0.14%

Insider Own	3.66%
Insider Trans	1.44%
Inst Own	24.24%
Inst Trans	0.63%
ROA	-110.14%
ROE	-149.98%
ROIC	-136.92%
Gross Margin	84.04%
Oper. Margin	-489.05%
Profit Margin	-469.02%
SMA20	-16.98%
SMA50	-28.17%
SMA200	-6.59%
Trades

Shs Outstand	48.19M
Shs Float	46.48M
Short Float	2.15%
Short Ratio	1.22
Short Interest	1.00M
52W High	2.59 -59.85%
52W Low	0.70 48.44%
Volatility	18.15% 12.02%
ATR (14)	0.15
RSI (14)	34.82
Beta	1.18
Rel Volume	0.99
Avg Volume	820.14K
Volume	815,165

Perf Week	-7.96%
Perf Month	-12.61%
Perf Quarter	-13.33%
Perf Half Y	26.83%
Perf YTD	23.79%
Perf Year	6.73%
Perf 3Y	-0.95%
Perf 5Y	-87.24%
Perf 10Y	-
Recom	1.00
Target Price	7.25
Prev Close	1.16
Price	1.04
Change %	-10.34%

Nov-05-26 09:03PM	RenovoRx Posts First $1 Million Quarter And Misses On EPS As Sequential Growth Slows And Q4 Targets Get Harder (Earnings Whispers) -9.16% -5.04%
04:05PM	RenovoRx Reports Record Third Quarter 2026 Revenue Exceeding $1 Million (GlobeNewswire)
Oct-28-26 08:54PM	RenovoRx Must Show Center Growth Can Turn A Raised Guide Into Another Record (Earnings Whispers)
08:30AM	RenovoRx to Participate at the Canaccord Genuity MedTech Diagnostics and Digital Health & Services Forum (GlobeNewswire)
Oct-22-26 08:45AM	RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026 (GlobeNewswire)
08:30AM	Loading…
Oct-07-26 08:30AM	RenovoRx Advances TAMP into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial (GlobeNewswire)
Oct-01-26 08:30AM	RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer (GlobeNewswire)
Sep-02-26 10:39AM	RenovoRx H.C. Wainwright Presentation to Highlight RenovoCath Growth and Phase III TIGeR-PaC Timeline (InvestorsHub) +19.43%
08:30AM	RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th (GlobeNewswire)
Aug-25-26 08:30AM	RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP Platform's Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer (GlobeNewswire) +13.60%
Aug-21-26 08:30AM	RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Aug-20-26 08:30AM	RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment (GlobeNewswire)
Aug-13-26 01:02AM	RenovoRx Inc (RNXT) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic Expansion ... (GuruFocus.com) +12.50%
Aug-12-26 04:05PM	RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth (GlobeNewswire)
Aug-11-26 09:26AM	RenovoRx Inc (RNXT) Q2 2026: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
08:30AM	Loading…
08:30AM	RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer (GlobeNewswire)
Aug-06-26 08:30AM	RenovoRx Announces First Commercial Clinical Use of RenovoCath in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors (GlobeNewswire) +8.49%
Aug-04-26 08:30AM	RenovoRx to Highlight TAMP Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August 13th (GlobeNewswire)
Jul-29-26 08:30AM	RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET (GlobeNewswire)
Jun-11-26 08:30AM	RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP in Locally Advanced Pancreatic Cancer (GlobeNewswire)
Jun-04-26 08:30AM	RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd (GlobeNewswire) +7.71%
May-28-26 08:30AM	RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer (GlobeNewswire) +6.20%
May-26-26 08:30AM	RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP Platform Presented at the 2026 ASCO Annual Meeting (GlobeNewswire)
May-19-26 08:30AM	RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th (GlobeNewswire)
May-15-26 01:01AM	RenovoRx Inc (RNXT) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Expansion (GuruFocus.com)
May-14-26 04:05PM	RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter (GlobeNewswire)
May-13-26 09:20AM	RenovoRx Inc (RNXT) Q1 2026 Earnings Report Preview: What To Expect (GuruFocus.com)
Apr-29-26 08:30AM	RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET (GlobeNewswire)
Apr-23-26 08:30AM	RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting (GlobeNewswire) -5.09%
Apr-14-26 08:30AM	Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx's TAMP Therapy Platform Presented at 2026 SIR Annual Scientific Meeting (GlobeNewswire)
08:30AM	Loading…
Apr-08-26 08:30AM	RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath Device for Targeted, Local Drug-Delivery via the Vasa Vasorum (GlobeNewswire)
Apr-01-26 02:20PM	RenovoRx Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026 (GlobeNewswire)
Mar-30-26 11:01PM	RenovoRx Inc (RNXT) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com) -5.31% -5.61%
04:05PM	RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Mar-27-26 09:19AM	Earnings To Watch: RenovoRx Inc (RNXT) Reports Q1 2026 Result (GuruFocus.com)
Mar-26-26 08:30AM	RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment (GlobeNewswire) +5.45%
Mar-23-26 08:30AM	RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement (GlobeNewswire) +11.00%
Mar-20-26 08:30AM	RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET (GlobeNewswire)
Mar-18-26 08:35AM	RenovoRx Announces $10 Million at Market Private Placement (GlobeNewswire) +6.59%
Mar-03-26 05:35PM	Oculis Holding AG (OCS) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -5.51%
Feb-28-26 09:01AM	RenovoRx advances RenovoCath adoption at U.S. cancer centers (TipRanks)
Feb-27-26 08:30AM	RenovoRx Advancing RenovoCath Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum (GlobeNewswire)
Feb-26-26 08:30AM	RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting (GlobeNewswire)
Feb-10-26 08:30AM	RenovoRx Establishes RenovoCath Medical Advisory Board (GlobeNewswire)
Feb-05-26 08:30AM	RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer (GlobeNewswire)
Feb-04-26 08:30AM	RenovoRx Announces Clinical Data Supporting the TAMP Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting (GlobeNewswire)
Jan-30-26 10:19AM	$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors (PR Newswire) +8.33%
Jan-28-26 08:30AM	RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting (GlobeNewswire)
Jan-20-26 08:30AM	RenovoRx Expands RenovoCath Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center (GlobeNewswire)
Jan-14-26 08:30AM	RenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026 (GlobeNewswire)
Jan-08-26 08:30AM	RenovoRx To Announce Promising New Clinical Data Using its TAMP Therapy Platform in an Abstract to be Presented at ASCO GI 2026 (GlobeNewswire) +13.86%
Dec-11-25 08:30AM	RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026 (GlobeNewswire)
Dec-08-25 09:00AM	Updated Lineup Announced for iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025 (ACCESSWIRE)
Dec-01-25 08:30AM	RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th (GlobeNewswire) -6.59%
Nov-19-25 08:30AM	RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th (GlobeNewswire) -6.38%
Nov-14-25 12:04AM	RenovoRx Inc (RNXT) Q3 2025 Earnings Call Highlights: Strong Commercial Momentum and Strategic ... (GuruFocus.com) -23.03%
Nov-13-25 05:30PM	RenovoRx, Inc. (RNXT) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	RenovoRx Reports Third Quarter 2025 Financial Results, Including Approximately $900,000 in Year-to-Date Revenue, and Provides Business Update (GlobeNewswire)
Nov-12-25 07:36AM	RenovoRx Inc (RNXT) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com) -6.54%
Nov-06-25 08:30AM	RenovoRx Strengthens Scientific Advisory Board (SAB) with Pancreatic Cancer Expert Timothy Donahue, MD (GlobeNewswire) -6.23%
Nov-04-25 08:30AM	RenovoRx CEO Shaun Bagai to Participate at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20th (GlobeNewswire) -6.42%
Oct-27-25 08:30AM	RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET (GlobeNewswire)
Oct-17-25 09:50AM	Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation (PR Newswire)
Oct-09-25 08:30AM	RenovoRx Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baere, MD, PhD (GlobeNewswire) -7.44%
Sep-25-25 08:30AM	RenovoRx's PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites (GlobeNewswire)
Sep-11-25 08:30AM	RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16th (GlobeNewswire) +5.98%
Aug-20-25 08:30AM	RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 27th Annual Global Investment Conference in New York City, September 8-10, 2025 (Business Wire) -5.58%
Aug-15-25 03:24AM	RenovoRx Inc (RNXT) Q2 2025 Earnings Call Highlights: Strong Market Demand and Strategic Trials ... (GuruFocus.com) -22.94%
Aug-14-25 05:20PM	RenovoRx, Inc. (RNXT) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review (Business Wire)
Aug-06-25 08:30AM	RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath Device with Growing Customer Demand and Key Leadership Hire (GlobeNewswire)
Jul-28-25 08:30AM	RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath Device to Solid Tumors (Business Wire)
Jul-14-25 08:30AM	RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET (Business Wire) +8.95%
Jun-05-25 11:00PM	RenovoRx (RNXT) PT Raised to $11.50 by Ascendiant on Strong Q1 2025 Results (Insider Monkey)
May-16-25 09:42AM	Q1 2025 RenovoRx Inc Earnings Call (Thomson Reuters StreetEvents) +6.31%
03:15AM	RenovoRx Inc (RNXT) Q1 2025 Earnings Call Highlights: Promising Revenue Growth and Clinical ... (GuruFocus.com)
May-15-25 07:30PM	RenovoRx, Inc. (RNXT) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +5.71%
04:05PM	RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights (Business Wire)
May-14-25 08:30AM	RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st (Business Wire)
May-06-25 08:30AM	U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP) Therapy Platform (Business Wire)
May-01-25 08:30AM	RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET (Business Wire)
Apr-29-25 08:30AM	Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRxs Ongoing Phase III TIGeR-PaC Clinical Trial (Business Wire)
Apr-16-25 08:30AM	RenovoRx Increases U.S. Production of RenovoCath Devices to Meet Growing Demand from Oncology Community (Business Wire) +14.44%
Apr-04-25 08:30AM	RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th (Business Wire)
Apr-01-25 08:30AM	RenovoRx Reports Initial Revenues from RenovoCath Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial (Business Wire)
Mar-28-25 08:00AM	RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting (Business Wire)
Mar-26-25 08:00AM	RenovoRx Pre-Clinical Results Supporting TAMP as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting (Business Wire)
Mar-20-25 08:00AM	RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET (Business Wire)
Mar-19-25 08:00AM	RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025 (Business Wire)
Feb-26-25 08:00AM	RenovoRx Advances Commercialization of RenovoCath with Several New Purchase Orders, Including Customer Reorders (Business Wire)
Feb-13-25 08:00AM	RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery (Business Wire) -11.21%
Feb-11-25 07:00AM	RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock (Business Wire)
Feb-07-25 03:11AM	RenovoRx Prices $12.1 Million Public Offering; Shares Decline Post-Announcement (GuruFocus.com) -20.55%
Feb-06-25 08:49PM	RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock (Business Wire)
04:05PM	RenovoRx Announces Proposed Public Offering (Business Wire)
Jan-27-25 12:48PM	ASCO GI: RenovoRXs TAMP system reduces side effects in pancreatic cancer (Clinical Trials Arena)
08:00AM	RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025 (Business Wire)
Jan-22-25 09:00AM	Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium (PR Newswire)
Jan-08-25 08:00AM	RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025 (Business Wire)
Dec-30-24 08:00AM	RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform (Business Wire) +6.92%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
VOLL MARK	Chief Financial Officer	May 19 '26	Buy	0.79	25,000	19,690	142,380	May 21 07:00 AM
Agah Ramtin	Chief Medical Officer	Jan 21 '26	Buy	1.00	10,000	9,975	798,460	Jan 22 07:00 AM
Agah Ramtin	Chief Medical Officer	Dec 31 '25	Buy	0.86	9,795	8,424	788,460	Jan 05 07:00 AM
Agah Ramtin	Chief Medical Officer	Dec 30 '25	Buy	0.83	205	169	778,665	Jan 02 05:00 PM
Bagai Shaun	Chief Executive Officer	Dec 18 '25	Buy	0.90	5,000	4,506	340,040	Dec 22 07:00 AM
Bagai Shaun	Chief Executive Officer	Dec 17 '25	Buy	0.85	5,000	4,262	335,040	Dec 19 07:00 AM
Agah Ramtin	Chief Medical Officer	Dec 16 '25	Buy	0.85	12,000	10,200	778,460	Dec 17 07:00 AM
Agah Ramtin	Chief Medical Officer	Dec 05 '25	Buy	0.96	10,000	9,600	766,460	Dec 08 07:00 AM
Agah Ramtin	Chief Medical Officer	Nov 24 '25	Buy	0.80	12,000	9,600	756,460	Nov 24 06:00 PM
Agah Ramtin	Chief Medical Officer	Nov 21 '25	Buy	0.80	10,000	8,000	744,460	Nov 24 06:00 PM

RenovoRx, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a therapy platform to deliver chemotherapy. Its therapy platform includes RenovoTAMP, a therapy platform designed for targeted delivery of chemotherapy enabling localized treatment of solid tumors. The company was founded by Ramtin Agah and Kamran Najmabadi in 2009 and is headquartered in Mountain View, CA.

FounderDr. Ramtin Agah M.D.

CEOMr. Shaun R. Bagai

CGMAMr. Ronald B. Kocak CPA

CFO & Principal Accounting OfficerMr. Mark Voll

Vice President of Quality & OperationsMr. Tom Kelly

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

RNXT

RenovoRx Inc

Upgrade your Finviz experience

All the Features.
Half the Price.